High-dose cyclophosphamide for severe systemic lupus erythematosus.

Area of Science:

• Rheumatology
• Immunology
• Oncology

Background:

• Systemic lupus erythematosus (SLE) is a severe autoimmune disease often requiring aggressive treatment.
• Cytotoxic therapy, particularly cyclophosphamide, is a standard treatment for severe SLE.
• High-dose cyclophosphamide has shown potential for inducing remission in autoimmune illnesses.

Purpose of the Study:

• To evaluate the efficacy and safety of high-dose cyclophosphamide (200 mg/kg) in patients with severe SLE.
• To assess the impact of this treatment on disease activity scores.
• To determine if stem cell rescue is necessary with this high-dose regimen.

Main Methods:

• Four patients with severe SLE received cyclophosphamide (200 mg/kg) over 4 days.
• Filgrastim was administered from day 10 until absolute neutrophil count recovery.
• Disease activity was assessed using SLAM-2, SLEDAI, and RILE scores before and after treatment.

Main Results:

• Patients had a mean SLE disease duration of 12.5 years and high baseline disease activity (SLAM-2: 15.5, SLEDAI: 23.25).
• At a median follow-up of 22 months, disease activity significantly decreased (SLAM-2: 6.25, SLEDAI: 7.75).
• All patients experienced febrile neutropenia, but no long-term morbidities or mortalities were observed.

Conclusions:

• High-dose cyclophosphamide (200 mg/kg) is a viable and effective therapy for decreasing disease severity in severe SLE patients with poor prognoses.
• This treatment can induce remission without necessitating stem cell rescue.
• Further research is warranted for refractory SLE and as a primary therapy for moderate to severe SLE cases.